Expertise in
7
conditions

Sung Y. Lee

Seoul, KR 
Expertise in
7
conditions
Seoul, KR 

Overview

Sung Lee practices practicing medicine in Seoul, Republic of Korea.

Lee is highly rated in 7 conditions, according to our data. Their clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Gamma Knife Radiosurgery, and Endoscopy.

They are actively involved in clinical research, co-authoring 130 peer reviewed articles and participating in 2 clinical trials.

Locations

Seoul, Republic of Korea
Other Locations
Ansan, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: March 04, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy
Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy
Enrollment Status: Unknown
Publish Date: July 15, 2021
Intervention Type: Drug
Study Drug: EGFR
Study Phase: Phase 2
View 1 Less Clinical Trial

130 Total Publications

Collagenous endobronchial obliteration after chemoradiation followed by consolidation osimertinib: a case report.
Collagenous endobronchial obliteration after chemoradiation followed by consolidation osimertinib: a case report.
Journal: Frontiers in oncology
Published: May 30, 2026

Frequently Asked Questions about Sung Y. Lee

Is Sung Y. Lee a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Sung Y. Lee is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sung Y. Lee participate in research or clinical trials?

Yes. Sung Y. Lee has published 130 articles and abstracts on conditions like Lung Cancer. You can view a list of Sung Y. Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lee's expertise for a condition
ConditionClose
    View All 29 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile